Diagnosis and treatment of neonatal diabetes: An United States experience

Pediatric Diabetes

Volumn 9, Issue 5, 2008, Pages 450-459

  Støy, Julie ^a,b   Greeley, Siri Atma W ^a   Paz, Veronica P ^a   Ye, Honggang ^a   Pastore, Ashley N ^a   Skowron, Kinga B ^a   Lipton, Rebecca B ^a   Cogen, Fran R ^c   Bell, Graeme I ^a   Philipson, Louis H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b AARHUS UNIVERSITY   (Denmark)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLIBENCLAMIDE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PROTEIN ABCC8; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CHROMOSOME 6P; CHROMOSOME ABERRATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; GLYCEMIC CONTROL; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; MUTATIONAL ANALYSIS; NEWBORN DIABETES MELLITUS; PRESCHOOL CHILD; PRIORITY JOURNAL; SALIVA; SEQUENCE ANALYSIS; UNITED STATES;

ADOLESCENT; ADULT; ATP-BINDING CASSETTE TRANSPORTERS; CHILD; CHILD, PRESCHOOL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; GLYBURIDE; HUMANS; INFANT; INFANT, NEWBORN; INSULIN; LEARNING DISORDERS; MALE; PEDIGREE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; UNITED STATES;

EID: 52649099443     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00433.x     Document Type: Article

References (35)

1. Edghill EL, Hattersley AT. Genetic disorders of the pancreatic beta cell and diabetes (permanent neonatal diabetes and maturity-onset diabetes of the young). In: Seino S, Bell GI, eds. Pancreatic Beta Cell in Health and Disease, 1st edn. Japan: Springer, 2008: 389-420.
2. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 2006: 49: 1190-1197.
3. Edghill EL, Dix RJ, Flanagan SE, Bingley PJ, Hattersley AT, Ellard S et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 2006: 55: 1895-1898.
4. Slingerland AS. Monogenic diabetes in children and young adults: challenges for researcher, clinician and patient. Rev Endocr Metab Disord 2006: 7: 171-185.
5. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 2007: 56: 1930-1937.
6. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006: 355: 456-466.
7. Støy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A 2007: 104: 15040-15044.
8. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997: 15: 106-110.
9. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000: 25: 406-409.
10. Njolstad PR, Sovik O, Cuesta -Munoz A, Bjorkhaug L, Massa O, Barbetti F et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001: 344: 1588-1592.
11. Vaxillaire M, Dechaume A, Busiah K, CavéH, Pereira S, Scharfmann R et al. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 2007: 56: 1737-1741.
12. Polak M, Dechaume A, CavéH, Nimri R, Crosnier H, Sulmont V et al. Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group. Diabetes 2008: 57: 1115-1119.
13. Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B et al. Insulin mutation screening in 1044 patients with diabetes: Mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008: 57: 1034-1042.
14. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004: 53: 2713-2718.
15. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006: 355: 467-477.
16. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004: 89: 5504-5507.
17. Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008: 31: 204-209.
18. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006: 7: 352-360.
19. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004: 350: 1838-1849.
20. Mackay DJ, Temple IK, Shield JP, Robinson DO. Bisulphite sequencing of the transient neonatal diabetes mellitus DMR facilitates a novel diagnostic test but reveals no methylation anomalies in patients of unknown aetiology. Hum Genet 2005: 116: 255-261.
21. Gardner RJ, Mackay DJ, Mungall AJ, Polychronakos C, Siebert R, Shield JP et al. An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet 2000: 9: 589-596.
22. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP. Transient neonatal diabetes: Widening the understanding of the etiopathogenesis of diabetes. Diabetes 2000: 49: 1359-1366.
23. Slingerland AS, Hurkx W, Noordam K, Flanagan SE, Jukema JW, Meiners LC et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 2008: 25: 277-281.
24. Slingerland AS, Nuboer R, Hadders -Algra M, Hattersley AT, Bruining GJ. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006: 49: 2559-2563.
25. Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 2007: 92: 1276-1282.
26. Massa O, Iafusco D, D'Amato E, Gloyn AL, Hattersley AT, Pasquino B et al. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 2005: 25: 22-27.
27. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004: 53: 2719-2722.
28. Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S. Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab 2007: 9 (Suppl. 2): 28-39.
29. Gach A, Wyka K, Malecki MT, Noczynska A, Skupien J, Nazim J et al. Islet-specific antibody seroconversion in patients with long duration of permanent neonatal diabetes caused by mutations in the KCNJ11 gene. Diabetes Care 2007: 30: 2080-2082.
30. Hermann R, Soltesz G. Prevalence and HLA association of GAD65 antibodies in Hungarian schoolchildren. Hum Immunol 2003: 64: 152-155.
31. Girard CA, Shimomura K, Proks P, Absalom N, Castano L, Perez de Nanclares G et al. Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes. Pflugers Arch 2006: 453: 323-332.
32. Gloyn AL, Cummings EA, Edghill EL, Harries LW, Scott R, Costa T et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004: 89: 3932-3935.
33. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea. J Clin Endocrinol Metab 2008: 93: 1054-1061.
34. Gloyn AL, Siddiqui J, Ellard S. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2006: 27: 220-231.
35. Battin M, Yong C, Phang M, Daaboul J. Transient neonatal diabetes mellitus and macroglossia. J Perinatol 1996: 16: 288-291.